Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
After many brand name GLP-1s were placed on the FDA drug shortage list, specialized pharmacies were granted limited permission to compound semaglutide and other similar peptide-based drugs for patients seeking to use them for weight loss purposes
Horowitz M, Edelbroek MA, Wishart JM, Straathof JW
Tirzepatide works by increasing insulin secretion, reducing glucagon secretion, and slowing down gastric emptying
Tirzepatide: first approval
Technical Information Compound Name: Retatrutide Peptide Classification: Triple Hormone Receptor Agonist (GLP-1 / GIP / Glucagon Receptor Agonist) Molecular Formula: CHNO Appearance: White to off-white lyophilized powder Solubility: Typically soluble in bacteriostatic water or suitable research-grade diluents Research Category: Metabolic and multi-receptor pathway research peptide Common Research Areas GLP-1, GIP, and glucagon receptor signaling Glucose-homeostasis investigations Appetite and satiety-related research Adipose and energy-balance studies Metabolic and obesity-related investigations Cardiometabolic and endocrine-signaling pathways For Laboratory and Research Use Only Not for human consumption or therapeutic use
